Add Yahoo as a preferred source to see more of our stories on Google. (COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in ...

Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.

In March, the FDA approved DexCom Inc‘s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...

Oct 24 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat Wall Street estimates for third-quarter revenue and profit on Thursday, helped by resilient demand for its continuous ...

DexCom has barely scratched the surface of its niche in the diabetes market. As a result of industry challenges, the stock's valuation has now come down. But from here, the stock looks well-positioned ...

Add Yahoo as a preferred source to see more of our stories on Google. (COLORADO SPRINGS) — FOX21 News has learned alternative ways people are getting around the shortage of the medical device called ...

We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other ...

DexCom reported disappointing earnings, missing estimates by 4% and lowering full-year growth expectations by ~$200 million. Sales in the U.S. market slowed, while international markets saw anemic ...

Feb 13 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with ...

This year started with healthy gains for DexCom (NASDAQ: DXCM) stock, but they didn't last long. The medical device stock is now down by about 53% from the high-water mark it set in April. DexCom ...

Abbott and DexCom depend heavily on continuous glucose monitoring (CGM) device sales. Vertex is developing therapies that could cure type 1 diabetes. If Vertex is successful, the CGM market could be ...